^
    Back
    Association details:
    Biomarker:KRAS G12A + BRAF D549N
    Cancer:Non Small Cell Lung Cancer
    Drug:beroterkib anhydrous (ASTX029) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    CT108 - A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors

    Published date:
    03/10/2021
    Excerpt:
    ASTX029 was administered orally daily...Two subjects, one with KRAS-G12A and BRAF-D549N non-small cell lung cancer (120 mg) and one with KRAS-G12D metastatic pancreatic cancer (200 mg), achieved partial responses.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2022
    Title:

    A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.

    Published date:
    05/26/2022
    Excerpt:
    ASTX029 was administered orally daily on a continuous basis in 21-day cycles...Four subjects had a partial response, including KRAS-G12A BRAF-D549N non-small cell lung cancer (NSCLC; Phase 1A: 120 mg treated 20.0 months); KRAS-G12D pancreatic cancer (Phase 1A: 200 mg treated 2.1 months); KRAS-G13D NSCLC (Phase 1B; treated 10.6 months); KRAS-G12S NSCLC (Phase 1B; treated 10.4 months and ongoing).
    DOI:
    10.1200/JCO.2022.40.16_suppl.9085